Precision NanoSystems

the staggered-herringbone platform (Ignite benchtop, Spark clinical, Blaze and Gemini commercial, Bio-Continuum continuous manufacturing) that set the de-facto LNP-process-development standard.

Country
Canada
Commercial Cytiva company NanoAssemblr Blaze/Gemini
Coverage
CNEUUS
fill-finish-packaging
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
FundingRaised approximately $25.4M to $37.6M in total funding over multiple rounds before acquisition by Danaher in 2021 medium confidencedrugdeliverybusiness.com
CapacityModular commercial formulation skid capacity of up to 384 L/h; capability to produce up to 240 million vaccine doses annually upon completion of biomanufacturing facilitycdn.cytivalifesciences.com · rtf.vc · prnewswire.com
CertificationATEX and IECEx rated systems; compliant with FDA 21 CFR Part 11 for electronic recordscdn.cytivalifesciences.com
Regulatory approvalQuality Management System aligned with ICH Q10 and 21 CFR Parts 210 and 211cdn.cytivalifesciences.com
Production siteVancouver, British Columbia, Canada and South San Francisco, California, USAcdn.cytivalifesciences.com · news-medical.net · richmondscientific.com

Independent sources: cdn.cytivalifesciences.com · drugdeliverybusiness.com · news-medical.net · prnewswire.com · richmondscientific.com · rtf.vc

Technologies
NameClusterRisk
mRNA / LNP manufacturing equipmentfill-finish-packagingLow

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.